MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Galderma

< Previous 1 2 3 Next >
News headline image
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
From Galderma
Via Business Wire
News headline image
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
From Galderma
Via Business Wire
News headline image
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
From Galderma
Via Business Wire
News headline image
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
From Galderma
Via Business Wire
News headline image
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
From Galderma
Via Business Wire
News headline image
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns
From Galderma
Via Business Wire
News headline image
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
From Galderma
Via Business Wire
News headline image
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
From Galderma
Via Business Wire
News headline image
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
From Galderma
Via Business Wire
News headline image
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
From Galderma
Via Business Wire
News headline image
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
From Galderma
Via Business Wire
News headline image
Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare
From Galderma
Via Business Wire
News headline image
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
From Galderma
Via Business Wire
News headline image
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
From Galderma
Via Business Wire
News headline image
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
From Galderma
Via Business Wire
News headline image
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
From Galderma
Via Business Wire
News headline image
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
From Galderma
Via Business Wire
News headline image
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
From Galderma
Via Business Wire
News headline image
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
From Galderma
Via Business Wire
News headline image
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
From Galderma
Via Business Wire
News headline image
Galderma Announces Appointment of New Chief Financial Officer
From Galderma
Via Business Wire
News headline image
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
From Galderma
Via Business Wire
News headline image
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
From Galderma
Via Business Wire
News headline image
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
From Galderma
Via Business Wire
News headline image
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
From Galderma
Via Business Wire
News headline image
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
From Galderma
Via Business Wire
News headline image
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio
From Galderma
Via Business Wire
News headline image
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
From Galderma
Via Business Wire
News headline image
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
From Galderma
Via Business Wire
News headline image
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis
From Galderma
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story